256 related articles for article (PubMed ID: 25920008)
1. Proteomics-level analysis of myelin formation and regeneration in a mouse model for Vanishing White Matter disease.
Gat-Viks I; Geiger T; Barbi M; Raini G; Elroy-Stein O
J Neurochem; 2015 Aug; 134(3):513-26. PubMed ID: 25920008
[TBL] [Abstract][Full Text] [Related]
2. Poor cerebral inflammatory response in eIF2B knock-in mice: implications for the aetiology of vanishing white matter disease.
Cabilly Y; Barbi M; Geva M; Marom L; Chetrit D; Ehrlich M; Elroy-Stein O
PLoS One; 2012; 7(10):e46715. PubMed ID: 23056417
[TBL] [Abstract][Full Text] [Related]
3. Mutant eIF2B leads to impaired mitochondrial oxidative phosphorylation in vanishing white matter disease.
Raini G; Sharet R; Herrero M; Atzmon A; Shenoy A; Geiger T; Elroy-Stein O
J Neurochem; 2017 Jun; 141(5):694-707. PubMed ID: 28306143
[TBL] [Abstract][Full Text] [Related]
4. A mouse model for eukaryotic translation initiation factor 2B-leucodystrophy reveals abnormal development of brain white matter.
Geva M; Cabilly Y; Assaf Y; Mindroul N; Marom L; Raini G; Pinchasi D; Elroy-Stein O
Brain; 2010 Aug; 133(Pt 8):2448-61. PubMed ID: 20826436
[TBL] [Abstract][Full Text] [Related]
5. Glial pathology in a novel spontaneous mutant mouse of the Eif2b5 gene: a vanishing white matter disease model.
Terumitsu-Tsujita M; Kitaura H; Miura I; Kiyama Y; Goto F; Muraki Y; Ominato S; Hara N; Simankova A; Bizen N; Kashiwagi K; Ito T; Toyoshima Y; Kakita A; Manabe T; Wakana S; Takebayashi H; Igarashi H
J Neurochem; 2020 Jul; 154(1):25-40. PubMed ID: 31587290
[TBL] [Abstract][Full Text] [Related]
6. The Energy Status of Astrocytes Is the Achilles' Heel of eIF2B-Leukodystrophy.
Herrero M; Daw M; Atzmon A; Elroy-Stein O
Cells; 2021 Jul; 10(8):. PubMed ID: 34440627
[TBL] [Abstract][Full Text] [Related]
7. eIF2B Mutations Cause Mitochondrial Malfunction in Oligodendrocytes.
Herrero M; Mandelboum S; Elroy-Stein O
Neuromolecular Med; 2019 Sep; 21(3):303-313. PubMed ID: 31134486
[TBL] [Abstract][Full Text] [Related]
8. A point mutation in translation initiation factor eIF2B leads to function--and time-specific changes in brain gene expression.
Marom L; Ulitsky I; Cabilly Y; Shamir R; Elroy-Stein O
PLoS One; 2011; 6(10):e26992. PubMed ID: 22073122
[TBL] [Abstract][Full Text] [Related]
9. Vanishing white matter disease expression of truncated EIF2B5 activates induced stress response.
Keefe MD; Soderholm HE; Shih HY; Stevenson TJ; Glaittli KA; Bowles DM; Scholl E; Colby S; Merchant S; Hsu EW; Bonkowsky JL
Elife; 2020 Dec; 9():. PubMed ID: 33300869
[TBL] [Abstract][Full Text] [Related]
10. Astrocytes are central in the pathomechanisms of vanishing white matter.
Dooves S; Bugiani M; Postma NL; Polder E; Land N; Horan ST; van Deijk AL; van de Kreeke A; Jacobs G; Vuong C; Klooster J; Kamermans M; Wortel J; Loos M; Wisse LE; Scheper GC; Abbink TE; Heine VM; van der Knaap MS
J Clin Invest; 2016 Apr; 126(4):1512-24. PubMed ID: 26974157
[TBL] [Abstract][Full Text] [Related]
11. Proteomic dissection of vanishing white matter pathogenesis.
Man JHK; Zarekiani P; Mosen P; de Kok M; Debets DO; Breur M; Altelaar M; van der Knaap MS; Bugiani M
Cell Mol Life Sci; 2024 May; 81(1):234. PubMed ID: 38789799
[TBL] [Abstract][Full Text] [Related]
12. Vanishing white matter: deregulated integrated stress response as therapy target.
Abbink TEM; Wisse LE; Jaku E; Thiecke MJ; Voltolini-González D; Fritsen H; Bobeldijk S; Ter Braak TJ; Polder E; Postma NL; Bugiani M; Struijs EA; Verheijen M; Straat N; van der Sluis S; Thomas AAM; Molenaar D; van der Knaap MS
Ann Clin Transl Neurol; 2019 Aug; 6(8):1407-1422. PubMed ID: 31402619
[TBL] [Abstract][Full Text] [Related]
13. Impaired eukaryotic translation initiation factor 2B activity specifically in oligodendrocytes reproduces the pathology of vanishing white matter disease in mice.
Lin Y; Pang X; Huang G; Jamison S; Fang J; Harding HP; Ron D; Lin W
J Neurosci; 2014 Sep; 34(36):12182-91. PubMed ID: 25186761
[TBL] [Abstract][Full Text] [Related]
14. Leukoencephalopathy with vanishing white matter: a review.
Bugiani M; Boor I; Powers JM; Scheper GC; van der Knaap MS
J Neuropathol Exp Neurol; 2010 Oct; 69(10):987-96. PubMed ID: 20838246
[TBL] [Abstract][Full Text] [Related]
15. Isocaloric low protein diet in a mouse model for vanishing white matter does not impact ISR deregulation in brain, but reveals ISR deregulation in liver.
Wisse LE; Visser D; Ter Braak TJ; Bakkali A; Struys EA; Morrison CD; van der Knaap MS; Abbink TEM
Nutr Neurosci; 2022 Jun; 25(6):1219-1230. PubMed ID: 33236691
[No Abstract] [Full Text] [Related]
16. [Eukaryotic translation initiation factor 2B and leukoencephalopathy with vanishing white matter].
Pan YX; Wu Y; Niu ZP; Jiang YW
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):608-10. PubMed ID: 19829687
[TBL] [Abstract][Full Text] [Related]
17. Eif2b3 mutants recapitulate phenotypes of vanishing white matter disease and validate novel disease alleles in zebrafish.
Lee YR; Kim SH; Ben-Mahmoud A; Kim OH; Choi TI; Lee KH; Ku B; Eum J; Kee Y; Lee S; Cha J; Won D; Lee ST; Choi JR; Lee JS; Kim HD; Kim HG; Bonkowsky JL; Kang HC; Kim CH
Hum Mol Genet; 2021 Apr; 30(5):331-342. PubMed ID: 33517449
[TBL] [Abstract][Full Text] [Related]
18. A Japanese girl with an early-infantile onset vanishing white matter disease resembling Cree leukoencephalopathy.
Takano K; Tsuyusaki Y; Sato M; Takagi M; Anzai R; Okuda M; Iai M; Yamashita S; Okabe T; Aida N; Tsurusaki Y; Saitsu H; Matsumoto N; Osaka H
Brain Dev; 2015 Jun; 37(6):638-42. PubMed ID: 25457085
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of safety and early efficacy of AAV gene therapy in mouse models of vanishing white matter disease.
Herstine JA; Chang PK; Chornyy S; Stevenson TJ; Sunshine AC; Nokhrina K; Rediger J; Wentz J; Vetter TA; Scholl E; Holaway C; Pyne NK; Bratasz A; Yeoh S; Flanigan KM; Bonkowsky JL; Bradbury AM
Mol Ther; 2024 Jun; 32(6):1701-1720. PubMed ID: 38549375
[TBL] [Abstract][Full Text] [Related]
20. Drug Screening Identifies Sigma-1-Receptor as a Target for the Therapy of VWM Leukodystrophy.
Atzmon A; Herrero M; Sharet-Eshed R; Gilad Y; Senderowitz H; Elroy-Stein O
Front Mol Neurosci; 2018; 11():336. PubMed ID: 30279648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
